MarketScott Reuben
Company Profile

Scott Reuben

Scott S. Reuben is an American anesthesiologist who falsified data heralding the benefits of the Pfizer pain medication Celebrex while downplaying its negative side effects.

Background
Reuben was educated at Columbia University. He graduated from medical school at the State University of New York at Buffalo in 1985 and undertook his anesthesiology residency at Mount Sinai Medical Center in New York City. Reuben fell under suspicion when Baystate conducted a routine audit in May 2008 which revealed that Reuben had not been given approval for two studies that he intended to present during the hospital's research week. On March 10, 2009 a Baystate spokeswoman announced that Reuben admitted to fabricating many of the data underlying his research. Reuben never conducted the clinical trials that he wrote about in 21 journal articles dating from at least 1996. Although Reuben often co-wrote papers with other researchers, Baystate found that the other researchers did not know about or participate in Reuben's studies, Reuben also wrote to the Food and Drug Administration, urging the agency not to restrict the use of many of the painkillers he studied, citing his own data on their safety and effectiveness. "His findings had a huge impact on the field." He also described Reuben's actions as the biggest case of fraud in the history of anesthesiology. Fellow editor Paul White believed that Reuben's fraudulent studies may have actually harmed patients due to the sale of "billions of dollars' worth of drugs" that caused slower recovery times. Reuben's work had actually come under scrutiny as early as 2007, when several anesthesiologists noticed his studies never showed negative results. Greg Koski, former director of the Office for Human Research Protections, said the fraud was unusual because Reuben was able to carry it on for almost 13 years without being caught by the peer review process. All of Reuben's 21 fraudulent articles, as well as the article abstracts, are documented in the magazine Healthcare Ledger. Tufts has since cut ties with Reuben, and his Massachusetts medical license was permanently revoked after a period in which he voluntarily agreed not to practice. == Sentencing ==
Sentencing
On January 7, 2010 Reuben agreed to plead guilty to one count of health care fraud. Prosecutors alleged that Reuben obtained thousands of dollars in grants for research that he never performed. He formally pleaded guilty on February 21, 2010 before Judge Michael Ponsor. On May 24, Ponsor sentenced him to six months in prison, followed by three years of supervised release. He was ordered to pay a $5,000 fine, forfeit $50,000 to the government and make $360,000 in restitution to pharmaceutical companies. The plea deal effectively ended his career as a doctor; most states will not grant medical licenses to convicted felons. On November 16, 2011 the U.S. Food and Drug Administration (FDA) issued an order permanently debarring Reuben from assisting in drug applications. ==Impact==
Impact
A 2009 review of systematic review articles used in evidence-based medicine found that while some reviews were no longer valid when the Reuben studies were removed, the conclusions in the majority of them remained unchanged. The review found that the key Reuben claims that needed to be re-examined were "the absence of detrimental effects of coxibs on bone healing after spine surgery, the beneficial long-term outcome after preemptive administration of coxibs including an allegedly decreased incidence of chronic pain after surgery, and the analgesic efficacy of ketorolac or clonidine when added to local anesthetics for intravenous regional anesthesia." == See also ==
tickerdossier.comtickerdossier.substack.com